

January 28, 2014

The Honorable Julia Lynn, Chairperson
Senate Committee on Commerce
Statehouse, Room 445-S
Topeka, Kansas 66612

Dear Senator Lynn:


SUBJECT: Fiscal Note for SB 292 by Senate Committee on Commerce

In accordance with KSA 75-3715a, the following fiscal note concerning SB 292 is respectfully submitted to your committee.

SB 292 would give the Kansas Bioscience Authority and the Secretary of Revenue the authority to determine that a company which has previously been determined to be a bioscience company is no longer considered as such for the purposes of the Emerging Industry Investment Act. The bill would take effect on July 1, 2014, and the determination to change status must be based on verifiable evidence.

The Department of Revenue notes that SB 292 would have no fiscal effect.

Sincerely,



Jon Hummell,
Interim Director of the Budget

cc: Steve Neske, Department of Revenue